Their targeting ability was believed to limit side effects for cancer patients and give a wider therapeutic window than other chemotherapeutic agents, although this promise hasn’t yet been realized in the clinic.ĪDC technologies have been featured in many publications, including scientific journals. After the ADC is internalized, the cytotoxin kills the cancer. The biochemical reaction that occurs upon attaching triggers a signal in the tumor cell, which then absorbs, or internalizes, the antibody together with the linked cytotoxin. Antibodies attach themselves to the antigens on the surface of cancerous cells. Mechanism of action Īn anticancer drug is coupled to an antibody that targets a specific tumor antigen (or protein) that, ideally, is only found in or on tumor cells. Antibody-drug conjugates are an example of bioconjugates and immunoconjugates.ĪDCs combine the targeting properties of monoclonal antibodies with the cancer-killing capabilities of cytotoxic drugs, designed to discriminate between healthy and diseased tissue. ĪDCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. As of 2019, some 56 pharmaceutical companies were developing ADCs. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. Schematic structure of an antibody-drug conjugate (ADC)Īntibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |